Month: January 2017

Breakthrough cancer drug venetoclax approved for use in Australia

Chronic lymphocytic leukaemia
Media releases
Research

Blood cancer A – Z

Acute lymphoblastic leukaemia (ALL)
Acute myeloid leukemia (AML)
Acute promyelocytic leukaemia (APML)
Adult T-cell lymphoma (ATLL)
Anaplastic large cell lymphoma (ALCL)
Amyloidosis
Aplastic anaemia (AA)
Biphenotypic leukaemia
Burkitt’s lymphoma
Chronic lymphocytic leukaemia (CLL)
Chronic myeloid leukaemia (CML)
CNS lymphoma
Diffuse large B-cell lymphoma (DLBCL)
Double hit lymphoma (DHL)
Essential Thrombocythaemia (ET)
Follicular lymphoma (FL)
Hairy cell leukaemia (HCL)
Hodgkin lymphoma (HL)
Leukaemia / Leukemia
Lymphoblastic lymphoma (LL)
Lymphoma
MALT lymphoma
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
Myelodysplastic neoplasms (MDS)
Myelofibrosis (MF)
Myeloma
Myeloproliferative neoplasms (MPN)
Non-Hodgkin lymphoma (NHL)
Peripheral T-cell lymphoma (PTCL)
Polycythaemia (Rubra) vera (PRV)
Skin lymphomas
Small lymphocytic lymphoma (SLL)
Waldenstrom’s macroglobulinaemia (WM)

The Leukaemia Foundation acknowledges the traditional owners of country throughout Australia and recognises their continuing connection to land, sea and community. We pay our respects to their Elders past, present and emerging.

The Leukaemia Foundation is committed to ensuring that everyone is treated with dignity regardless of their ability, cultural background, religion, ethnicity, gender identity, intersex status or sexual orientation.

Need to talk?

Speak with our Blood Cancer Support Coordinators via our Online Blood Cancer Support Service or via 1800 620 420

Sign up for news

Keep up to date with what's happening in the world of blood cancer.

Subscribe today

Join our Facebook groups

Express concerns, ask questions and share information on living with blood cancer.

Join our networks

Connect with us

Privacy
Disclaimer
Site map
Contact us

Breakthrough cancer drug venetoclax approved for use in Australia

Recent Posts